OHSU in the news

Immunity level came at the cost of lives

The Mail Tribune October 08, 2021
An editorial cites an OHSU estimate of statewide COVID-19 immunity while highlighting the large number of residents in Jackson and Josephine counties who have become infected with the novel coronavirus.

AbbVie's Upadacitinib (RINVOQ®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

AbbVie October 07, 2021
"Non-radiographic axial spondyloarthritis affects a younger adult patient population which can have a significant impact during prime years of those dealing with the disease," said Atul Deodhar, M.D., professor of medicine and medical director of the Rheumatology Clinics for the Division of Arthritis and Rheumatic Diseases at Oregon Health & Science University. "These data show that upadacitinib has the potential to improve non-radiographic axial spondyloarthritis symptoms and help patients take control of their disease."

Proposed residency fixes: Are they realistic or just wishful thinking?

Medscape October 07, 2021
While discussing the findings and recommendations in a report he helped compile as part of a Coalition for Physician Accountability committee, George Mejicano, M.D., says: “Are we really producing what the doctors of the country need? I would argue, no."
See more stories